MBBS: University of Delhi, New Delhi, India, 1985.
MD: University of Delhi, New Delhi, India, 1989.
MS: University of Maryland, Baltimore, MD, 1991.
Fellowship: Children's Hospital Los Angeles, University of Southern California, 1995.
Cancer and Blood Diseases, Sickle Cell and Hemoglobin Disorders
Experimental Hematology and Cancer Biology, Cancer and Blood Diseases, Hematology
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Preclinical Evaluation of Foamy Virus Vector-Mediated Gene Addition in Human Hematopoietic Stem/Progenitor Cells for Correction of LAD-1.
Smith, RH; Bloomer, H; Fink, D; Keyvanfar, K; Nasimuzzaman, M; Sancheznieto, F; Dutta, R; Guenther Bui, K; Alvarado, LJ; Bauer, TR; et al.
Human Gene Therapy.
NRASQ61R mutation in human endothelial cells causes vascular malformations.
Boscolo, E; Pastura, P; Schrenk, S; Goines, J; Kang, R; Pillis, D; Malik, P; Le Cras, TD.
Differential CXCR4 expression on hematopoietic progenitor cells versus stem cells directs homing and engraftment.
Felker, S; Shrestha, A; Bailey, J; Pillis, DM; Siniard, D; Malik, P.
Successful use of veno-venous extracorporeal membrane oxygenation for acute chest syndrome in a child with sickle cell disease and SARS-CoV-2.
Koh, W; Malik, P; Whitehead, J; Morales, DL S; Hayes, D.
Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI).
Adair, JE; Androski, L; Bayigga, L; Bazira, D; Brandon, E; Dee, L; Deeks, S; Draz, M; Dubé, K; Dybul, M; et al.
Rapid and automated quantitation of dense red blood cells: A robust biomarker of hydroxyurea treatment response.
Sadaf, A; Quinn, CT; Korpik, JB; Pfeiffer, A; Reynaud, M; Niss, O; Malik, P; Ware, RE; Kalfa, TA; McGann, PT.
Blood Cells, Molecules, and Diseases.
Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia.
Quinn, CT; Niss, O; Dong, M; Pfeiffer, A; Korpik, J; Reynaud, M; Bonar, H; Kalfa, TA; Smart, LR; Malik, P; et al.
British Journal of Haematology.
Cardiac pathophysiology in sickle cell disease.
Gbotosho, OT; Taylor, M; Malik, P.
Journal of Thrombosis and Thrombolysis.
Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience.
Karkoska, K; Todd, K; Niss, O; Clapp, K; Fenchel, L; Kalfa, TA; Malik, P; Quinn, CT; Ware, RE; McGann, PT.
Pediatric Blood and Cancer.
FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice.
Shrestha, A; Chi, M; Wagner, K; Malik, A; Korpik, J; Drake, A; Fulzele, K; Guichard, S; Malik, P.
Punam Malik, MD, Omar Niss, MD4/15/2020
Punam Malik, MD6/27/2019
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462
© 1999-2022 Cincinnati Children's Hospital Medical Center. All rights reserved.